Full-Time

Head of R&P

Payroll, Absence & Time Digital Product Lines

Confirmed live in the last 24 hours

Sanofi

Sanofi

10,001+ employees

Develops pharmaceuticals and vaccines globally

No salary listed

Senior, Expert

Sant Cugat del Vallès, Barcelona, Spain

Hybrid position

Category
Product Management
Product
Requirements
  • Minimum of 10 years of experience in digital product management or HR technology strategy
  • At least 5 years in a leadership role overseeing reward and performance management systems and technology portfolios
  • Extensive experience in managing the configuration of Workday’s compensation and absence modules
  • Knowledge of benefits and wellness vendor integrations
  • Experience managing interfaces with local payroll and time management systems
  • Proven leadership skills with a demonstrated ability to manage cross-functional teams through complex global technology initiatives
  • Excellent verbal and written communication skills
  • Bachelor’s degree in Business, Technology, Human Resources, or a related field
Responsibilities
  • Lead the product management team responsible for the global configuration and support of reward and performance solutions within the Workday tenant
  • Oversee the configuration of Workday’s compensation and advanced compensation modules
  • Manage the integration of benefits and wellness vendors with Workday
  • Lead the design and management of the core model for interfacing Workday with local payroll and time management systems
  • Drive the execution of the strategic roadmap for reward and performance digital products
  • Oversee the end-to-end process design for reward and performance management
  • Partner with Centers of Excellence (CoEs), Digital Products, People Services, and local market HR teams
Desired Qualifications
  • Advanced degree or relevant certifications in HRIS, Workday, or reward management
  • Advanced skills in Agile Mindset and Practices
  • Advanced skills in Consumer Experience
  • Advanced skills in Digital strategy & Governance
  • Advanced skills in Project Management & planning

Sanofi provides healthcare solutions through its pharmaceutical and biotechnology products, focusing on treatments and vaccines for various medical conditions. The company conducts extensive research and development to create new therapies and improve existing ones, particularly in areas like immunology, oncology, and rare diseases. Sanofi's products include prescription medicines, over-the-counter items, and vaccines, which are distributed to patients, healthcare professionals, and governments worldwide. What sets Sanofi apart from its competitors is its strong emphasis on scientific innovation and strategic partnerships, allowing it to maintain a diverse product pipeline and adapt to different regulatory environments. The company's goal is to enhance health outcomes and improve the quality of life for people globally.

Company Size

10,001+

Company Stage

IPO

Headquarters

Paris, France

Founded

1973

Simplify Jobs

Simplify's Take

What believers are saying

  • Sanofi's focus on personalized medicine offers opportunities in rare disease therapies.
  • mRNA technology expansion provides new vaccine development opportunities for Sanofi.
  • Sanofi's digital health solutions enhance its patient-centric approach and care delivery.

What critics are saying

  • Increased competition in the multiple sclerosis market may impact Sanofi's market share.
  • Potential EU regulatory hurdles could delay tolebrutinib's market entry.
  • Integration challenges from Dren Bio acquisition may affect expected synergies and outcomes.

What makes Sanofi unique

  • Sanofi's tolebrutinib targets smoldering neuroinflammation, a unique approach in multiple sclerosis treatment.
  • Dupixent shows promise as the first targeted treatment for bullous pemphigoid.
  • Sanofi's acquisition of Dren Bio enhances its biopharmaceutical capabilities and product pipeline.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Professional Development Budget

Parental Leave

Company News

PharmiWeb
Mar 25th, 2025
Availability Of The Q1 2025 Aide Mémoire

Paris, France – March 24, 2025. Sanofi announced today that its Q1 2025 Aide mémoire is available on the "Investors" page of the company's website:First quarter 2025 (sanofi.com)As for each quarter, Sanofi prepared this document to assist in the financial modelling of the Group's quarterly results. This document includes a reminder on various non-comparable items and exclusivity losses as well as the foreign currency impact and share count. Sanofi's first quarter 2025 results will be published on April 24, 2025.About SanofiWe are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people’s lives. Our team, across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions.Sanofi is listed on EURONEXT: SAN and NASDAQ: SNYMedia RelationsSandrine Guendoul | + 33 6 25 09 14 25 | sandrine.guendoul@sanofi.comEvan Berland | + 1 215 432 0234 | evan.berland@sanofi.comNicolas Obrist | + 33 6 77 21 27 55 | nicolas.obrist@sanofi.comLéo Le Bourhis | + 33 6 75 06 43 81 | leo.lebourhis@sanofi.comVictor Rouault | + 33 6 70 93 71 40 | victor.rouault@sanofi.comTimothy Gilbert | + 1 516 521 2929 | timothy.gilbert@sanofi.comInvestor RelationsThomas Kudsk Larsen | + 44 75 45 51 36 93| thomas.larsen@sanofi.comAlizé Kaisserian | + 33 6 47 04 12 11 | alize.kaisserian@sanofi.comFelix Lauscher | + 1 908 612 7239 | felix.lauscher@sanofi.comKeita Browne | +1 781 249 1766 | keita.browne@sanofi.comNathalie Pham | + 33 7 85 93 30 17 | nathalie.pham@sanofi.comTarik Elgoutni | + 1 617 710 3587 | tarik.elgoutni@sanofi.comThibaud Châtelet | + 33 6 80 80 89 90 | thibaud.chatelet@sanofi.comYun Li | + 33 6 84 00 90 72 | yun.li3@sanofi.comForward-looking statementsThis press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended

PharmiWeb
Mar 25th, 2025
Tolebrutinib Regulatory Submission Accepted For Priority Review In The Us For Patients With Multiple Sclerosis

If approved, tolebrutinib would be the first and only brain-penetrant BTK inhibitor to both treat non-relapsing secondary progressive multiple sclerosis (MS) and slow disability accumulation independent of relapse activityTolebrutinib has the potential to be the first therapy to target smoldering neuroinflammation, a key driver of disability accumulation in MSTolebrutinib was granted breakthrough therapy designation by the FDA based on positive results from the HERCULES phase 3 study in adults with non-relapsing secondary progressive MSParis, March 25, 2025. The US Food and Drug Administration (FDA) is evaluating under priority review the regulatory submission of tolebrutinib to treat non-relapsing secondary progressive multiple sclerosis (nrSPMS) and to slow disability accumulation independent of relapse activity in adult patients. The target action date for the FDA decision is September 28, 2025. A regulatory submission is also under review in the EU.The regulatory submissions in the US and the EU are supported by the results from the phase 3 studies HERCULES in nrSPMS and GEMINI 1 and 2 in relapsing MS (RMS). The findings from these studies, as well as additional clinical and preclinical studies, support the differentiated mechanism of tolebrutinib to target disability progression independent of relapse activity, and the scientific hypothesis that smoldering neuroinflammation represents a key inflammatory process in MS and is a critical driver of disability accumulation.Erik Wallström, MD, PhDGlobal Head of Neurology Development“The totality of data across our clinical program validates our scientific understanding of smoldering neuroinflammation as a distinct inflammatory process in MS. People living with non-relapsing secondary progressive multiple sclerosis or who experience disability independent of relapse activity suffer from disability that worsens over time due to persistent inflammation in the brain, known as smoldering neuroinflammation, which is the primary driver of disability

BNE
Mar 20th, 2025
Serbian biotech Dren Bio sold to Sanofi for $1.9bn

Pharma-major Sanofi has acquired Serbian-founded biopharmaceutical company Dren Bio for up to $1.9bn, the companies announced in a press release on ...

PharmiWeb
Mar 10th, 2025
Dupixent Late-Breaking Positive Pivotal Data In Bullous Pemphigoid Presented At Aad

Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant reductions were also seen in disease severity and itchDupixent also significantly reduced oral corticosteroid and rescue medicine use compared to placeboData support the potential of Dupixent to be the first and only targeted medicine to treat bullous pemphigoid, a skin disease with underlying type 2 inflammation; regulatory submissions are under review in the US and the EUParis and Tarrytown, NY, March 8, 2025. Positive results from the pivotal ADEPT phase 2/3 study evaluating the investigational use of Dupixent (dupilumab) in adults with moderate-to-severe bullous pemphigoid (BP) were shared in a late-breaking oral presentation at the 2025 American Academy of Dermatology (AAD) Annual Meeting. BP is a chronic, debilitating, and relapsing skin disease with underlying type 2 inflammation and characterized by intense itch and blisters, reddening of the skin, and painful lesions.Victoria Werth, MDChief of the Division of Dermatology at the Philadelphia Veterans Administration Hospital, Professor of Dermatology and Medicine at the Hospital of the University of Pennsylvania and the Veteran's Administration Medical Center, and principal investigator of the study“People with bullous pemphigoid live with unrelenting itch, blisters, and painful lesions that can be debilitating and make it difficult to function daily. Moreover, current treatment options can be challenging for this primarily elderly patient population because they work by suppressing their immune system. By targeting the underlying type 2 inflammation, which is a key driver for bullous pemphigoid, Dupixent is the first investigational biologic to show sustained disease remission and reduce disease severity and itch compared to placebo in a clinical study.”The ADEPT study met all primary and key secondary endpoints, enrolling 106 adults with moderate-to-severe BP who were randomized to receive Dupixent 300 mg (n=53) every two weeks after an initial loading dose or placebo (n=53) added to standard-of-care oral corticosteroids (OCS). During treatment, all patients underwent a protocol-defined OCS tapering regimen if control of disease activity was maintained

Sanofi
Mar 7th, 2025
Press release: Sanofi successfully prices EUR 1.5 billion of bond issue

Sanofi successfully prices EUR 1.5 billion of bond issue  Paris, March 5, 2025. Sanofi announces that it has successfully priced its offering of EUR 1.5 billion of notes across 2 tranches: €850...